Although orlistat is an inhibitor of FASN which is reported to be required by Mφ for phagocytic ability and other activation associated functions [4–9], orlistat-administration to tumor-bearing mice did not inhibit the expression of FASN in BMC or BMDM (data not shown). This evidence concerns the gene FASN and neoplasm.